ZBH · Zimmer Biomet reported Q3 2026 net sales of $2.063B (+3.1% reported,…

Zimmer Biomet reported Q3 2026 net sales of $2.063B (+3.1% reported, +3.7% constant currency) and adjusted diluted EPS of $1.90, in line with the prior year period. GAAP diluted EPS was $1.00, down 13.8% YoY. The company raised full-year 2026 organic constant currency revenue growth guidance to 3.0%-3.5% (from 2.25%-3.25%) and adjusted EPS guidance to $8.50-$8.60 (from $8.47-$8.59).

• Q3 2026 net sales $2.063B, +3.1% reported, +3.7% constant currency YoY
• GAAP diluted EPS $1.00, down 13.8% YoY from $1.16
• Adjusted diluted EPS $1.90, consistent with prior year period
• Full-year 2026 organic constant currency revenue growth guidance raised to 3.0%-3.5% from 2.25%-3.25%